DAIC

FEBRUARY 10, 2025

6, 2025 Eko Health, a leader in applying artificial intelligence (AI) for the early detection of heart and lung diseases, recently announcedpublication of a peer-reviewed study evaluating its novel algorithm for the detection of pulmonary hypertension (PH). tim.hodson Mon, 02/10/2025 - 12:43 Feb.

Research 64

Research Innovation Pulmonary Hypertension 64

The New England Journal of Medicine

APRIL 5, 2024

A number of therapies that have been shown to be effective in patients with chronic heart failure, including beta-blockers, mineralocorticoid receptor antagonists, and renin–angiotensin system inhibitors, have also been shown to be beneficial in patients with evidence of left ventricular systolic dysfunction, pulmonary congestion, or both after an (..)

Heart Failure 74

Heart Failure Myocardial Infarction Pulmonary 74

Open Heart

OCTOBER 1, 2024

We aimed to investigate whether our artificial intelligence (AI)-powered ECG analysis reliably distinguishes between the causes of dyspnoea and evaluate its potential as a clinical triage tool for comparing conventional heart failure diagnostic processes using natriuretic peptides.

Pulmonary 98

Pulmonary Heart Failure 98

DAIC

DECEMBER 19, 2023

These “off the shelf” mesenchymal stem cells (MSC) utilized for the study treatment are immunomodulatory with potential for impact on inflammatory processes in heart failure and have been shown to release multiple critical angiogenic factors that can enhance microvascular function and capillary networks in ischemic tissues.

Heart Failure 105

Heart Failure Interventional Cardiology Pulmonary Heart Disease 105

Journal of Cardiothoracic Surgery

AUGUST 27, 2024

It is controversial whether pulmonary function testing should be performed routinely in cardiac surgery patients. The aim of our study was to focus on patients who have congestive heart failure, caused by left.

Heart Failure 52

Heart Failure Pulmonary Research 52

American College of Cardiology

JULY 29, 2024

The goal of the CAMEO-DAPA trial was to assess whether dapagliflozin, a sodium-glucose cotransporter-2 inhibitor (SGLT2i), affects rest and exercise pulmonary capillary wedge pressure (PCWP) in patients with heart failure with preserved ejection fraction (HFpEF).

Preserved Ejection Fraction 61

Preserved Ejection Fraction Heart Failure Exercise Pulmonary 61

Frontiers in Cardiovascular Medicine

JANUARY 21, 2025

It can be associated with reduced quality of life and complications such as heart failure and stroke. Pulmonary vein isolation (PVI) is the most effective treatment for rhythm control. Atrial fibrillation is the most prevalent arrhythmia with a lifetime risk of nearly 30%.

Atrial Fibrillation 52

Atrial Fibrillation Quality of Life Ablation Electrophysiology 52

Becker's Hospital Review - Cardiology

JANUARY 13, 2025

"CMS proposes Medicare and Medicaid coverage for implantable pulmonary artery pressure sensors to manage heart failure. Final decision to be published on Jan.

CMS 52

CMS Heart Failure Medicaid Medicare 52

American College of Cardiology

AUGUST 7, 2024

In this week’s View, Dr. Eagle looks at post-capillary pulmonary hypertension in heart failure and the revised European guideline definition. He then explores obesity in adolescents and its impact on our societal health.

Obesity 61

Obesity Pulmonary Hypertension TAVR 61

Journal of the American Heart Association

FEBRUARY 3, 2025

BackgroundDespite the poor outcomes related to the presence of pulmonary hypertension, it often goes undiagnosed in part because of low suspicion and screening tools not being easily accessible such as echocardiography. Each 15second PCG, recorded using a digital stethoscope, was processed to generate 5second melspectrograms.

Pulmonary 68

Pulmonary Hypertension Echocardiogram Physiology 68

Heart BMJ

DECEMBER 23, 2024

Current guideline indications for intervention in asymptomatic patient are centred on left ventricular dimensions and ejection fraction and may include consideration in atrial fibrillation, pulmonary hypertension and those with left atrial dilatation.

Bicuspid/Mitral 59

Bicuspid/Mitral Atrial Fibrillation Heart Failure Pulmonary 59

DAIC

JUNE 4, 2024

American College of Cardiology (ACC) and American Heart Association (AHA) Issue New Hypertrophic Cardiomyopathy (HCM) Management Guidelines 2. New Study Published in JACC: Heart Failure Reveals that Despite Significant Efforts to Improve Acute Heart Failure Treatment Over the Past 20 Years, Management Remains Unchanged 3.

Preserved Ejection Fraction 105

Preserved Ejection Fraction Peripheral Arterial Disease Heart Failure Atrial Fibrillation 105

Circulation: Heart Failure

APRIL 14, 2025

Circulation: Heart Failure, Ahead of Print. BACKGROUND:Hemodynamically guided management of patients with chronic heart failure (HF), using a remote, ambulatory pulmonary artery (PA) pressure monitor, has been shown to reduce mortality and morbidity.

Heart Failure 40

Heart Failure Pulmonary Outcomes Circulation 40

Frontiers in Cardiovascular Medicine

NOVEMBER 17, 2024

BackgroundAnemia is a common complication in patients with heart failure and is associated with left ventricular systolic dysfunction.

Preserved Ejection Fraction 59

Preserved Ejection Fraction Heart Failure Tricuspid Atrial Fibrillation 59

Frontiers in Cardiovascular Medicine

MARCH 14, 2024

Extracorporeal membrane oxygenation (ECMO) and extracorporeal life support (ECLS) devices are well-established adjunctive treatment measures for patients with heart failure. However, the role of ECMO as a bridge to definitive therapy in a setting of acute heart failure is less established.

Bicuspid/Mitral 69

Bicuspid/Mitral Heart Failure COVID-19 Inpatient 69

Becker's Hospital Review - Cardiology

OCTOBER 31, 2024

"CMS has proposed coverage of implantable pulmonary artery pressure sensors for heart failure management. Learn about the criteria and public comment period."

CMS 52

CMS Pulmonary Heart Failure 52

DAIC

APRIL 22, 2024

RELIEVE-HF failed to meet its primary efficacy endpoint and did not reduce heart failure events or improve quality of life in heart failure patients with a preserved ejection fraction (HFpEF).

Preserved Ejection Fraction 105

Preserved Ejection Fraction Quality of Life Heart Failure Pacemaker 105

Circulation: Heart Failure

JANUARY 8, 2025

Circulation: Heart Failure, Ahead of Print. Overall, the mean pulmonary capillary wedge pressure before LVAD implantation was 259 mm Hg. The primary outcome was 1-year survival. The median follow-up was 364 days (interquartile range, 326381 days).

Quality of Life 76

Quality of Life Heart Failure Pulmonary Cardiomyopathy 76

Frontiers in Cardiovascular Medicine

FEBRUARY 11, 2024

Background Pulmonary arterial hypertension (PAH) is a severe and rare disease in the cardiopulmonary system. Its pathogenesis involves vascular remodeling of the pulmonary artery, which results in progressive increases in pulmonary arterial pressure.

Pulmonary 59

Pulmonary Hypertension Heart Failure 59

Medical Xpress - Cardiology

MARCH 4, 2025

In the 1980s, when Stella Kourembanas, MD, began her career in neonatology, she cared for newborns with pulmonary hypertension, a disease that results in abnormally high blood pressure in the lung arteries and can lead to heart failure. But pulmonary hypertension still persists.

Pulmonary 46

Pulmonary Hypertension Blood Pressure Heart Failure 46

Journal of the American Heart Association

DECEMBER 29, 2023

Journal of the American Heart Association, Ahead of Print. BackgroundPulmonary hypertension (PH) is highly prevalent in patients with heart failure with preserved ejection fraction (HFpEF), and it is a strong predictor of adverse outcomes. TAPSE/PASP and TAS’/PASP can be useful parameters to detect PH in patients with HFpEF.

Preserved Ejection Fraction 40

Preserved Ejection Fraction Pulmonary Heart Failure Hypertension 40

Circulation: Heart Failure

JULY 11, 2024

Circulation: Heart Failure, Ahead of Print.

Heart Failure 40

Heart Failure Pulmonary Circulation 40

American College of Cardiology

JUNE 28, 2024

™s Cordellaâ„¢ Pulmonary Artery Sensor System for the treatment of patients with NYHA class III heart failure (HF). Food and Drug Administration (FDA) on June 24 gave premarket approval for Endotronix, Inc.’s

Pulmonary 45

Pulmonary Heart Failure Article 45

American College of Cardiology

AUGUST 26, 2024

The goal of the MONITOR-HF trial was to compare the therapeutic effect(s) and safety profile of remote invasive hemodynamic monitoring with the CardioMEMS-HF system versus standard of care in New York Heart Association (NYHA) functional class III heart failure (HF) irrespective of left ventricular ejection fraction (LVEF).

Heart Failure 40

Heart Failure Pulmonary Article 40

Frontiers in Cardiovascular Medicine

JANUARY 28, 2025

ObjectiveClinical practice currently faces a significant shortfall in specific biomarkers needed for diagnosing right ventricular (RV) remodeling in patients with pulmonary hypertension (PH). ResultsPAB rats exhibited severe RV hypertrophy, fibrosis and enlargement of RV cardiomyocytes compared with sham group.

Biomarkers 52

Biomarkers Circulation Heart Failure Pulmonary 52

DAIC

JULY 10, 2024

a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, announced success from a collaborative Phase II trial of ProtheraCytes for the treatment of acute myocardial infarction (AMI) led by CellProthera , as well as plans to continue the relationship into Phase III.

Myocardial Infarction 105

Myocardial Infarction Heart Failure Heart Attack Heart attacks 105

European Journal of Heart Failure

APRIL 17, 2024

The interplay of MR and HFpEF: understanding increased pulmonary pressures and strategies for management. HFpEF, heart failure with preserved ejection fraction; MR, mitral valve regurgitation. Abstract Mitral regurgitation (MR) is highly prevalent among patients with heart failure and preserved ejection fraction (HFpEF).

Preserved Ejection Fraction 40

Preserved Ejection Fraction Bicuspid/Mitral Heart Failure Pulmonary 40

Coronary Artery Disease Journal

JUNE 2, 2024

Aim The aim of this study was to determine the best clinical predictors of acute heart failure needing mechanical ventilation (MV) in the first 48 h of evolution of patients admitted because of acute coronary syndrome (ACS). Methods We analyzed a cohort of patients admitted for ACS between February 2017 and February 2018.

Heart Failure 40

Heart Failure Pulmonary Ultrasound Myocardial Infarction 40

ECG Cases

DECEMBER 15, 2021

In this Part 1 of our two-part series on acute heart failure, Anton is joined by Dr. Tarlan Hedayati and Dr. Bourke Tillman to answer such questions as: how does PoCUS compare with clinical assessment and CXR in diagnostic accuracy for acute heart failure? and many more.

Heart Failure 52

Heart Failure Blood Pressure Pulmonary 52

Journal of the American Heart Association

APRIL 16, 2025

Journal of the American Heart Association, Ahead of Print. BackgroundAortic stenosis can lead to cardiac adaptations and symptoms similar to heart failure with preserved ejection fraction. Methods and ResultsThis retrospective cohort study included 469 patients with moderate aortic stenosis.

Preserved Ejection Fraction 40

Preserved Ejection Fraction Aortic valve Aortic Heart Failure 40

Open Heart

NOVEMBER 25, 2022

Objective The role of hyperuricaemia as a prognostic maker has been established in chronic heart failure (HF) but limited information on the association between plasma uric acid (UA) levels and central haemodynamic measurements is available. Median UA was 0.48 (0.39–0.61) mmol/L.

Heart Failure 52

Heart Failure Outcomes Heart Transplant Artificial Heart 52

Open Heart

SEPTEMBER 11, 2023

Objectives Inferior vena cava (IVC) diameter may be a surrogate for volume status in acute decompensated heart failure (ADHF). IVC diameter correlated to pulmonary arterial (PA) pressure (R=0.347, p<0.001) and body surface area (BSA) (R=0.424 p<0.001). The utility of IVC diameter measurement is under studied.

Heart Failure 52

Heart Failure Tricuspid Echocardiogram Pulmonary 52

European Journal of Heart Failure

DECEMBER 7, 2023

Increasing severity of obesity is associated with multiple characteristics that may contribute to the development or worsening of heart failure (HF) with preserved ejection fraction (HFpEF). Pulmonary vascular resistance at rest and exercise decreased with higher BMI.

Preserved Ejection Fraction 40

Preserved Ejection Fraction Obesity Heart Failure BMI 40

European Journal of Heart Failure

OCTOBER 30, 2023

Haemodynamic curve morphology is displayed for right atrial (RAP), right ventricular (RVP), mean pulmonary artery (PAP), and pulmonary capillary wedge pressure (PAWP). 2–4 points denotes an intermediate risk for heart failure with preserved ejection fraction (HFpEF) at non-invasive testing at rest.

Preserved Ejection Fraction 40

Preserved Ejection Fraction Heart Failure Exercise Pulmonary 40

European Journal of Heart Failure

JANUARY 10, 2025

Abstract Aims A cardiovascular magnetic resonance (CMR) approach to non-invasively estimate left ventricular (LV) filling pressure was recently developed and shown to correlate with invasively measured pulmonary capillary wedge pressure (PCWP).

Heart Failure 40

Heart Failure Pulmonary Ultrasound Diabetes 40

DAIC

JULY 31, 2024

a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, reported it has submitted a 510(k) for approval of its patented Morph DNA Steerable Introducer Sheath. mtaschetta-millane Wed, 07/31/2024 - 07:00 July 31, 2024 — BioCardia, Inc. ,

Myocardial Infarction 99

Myocardial Infarction Technology Angina Pulmonary 99

Circulation: Cardiovascular Quality & Outcomes

JANUARY 27, 2025

BACKGROUND:The absence of practice standards in vasoactive agent usage for acute decompensated heart failure has resulted in significant treatment variability across hospitals, potentially affecting patient outcomes. had pulmonary congestion and tissue hypoperfusion status, respectively. female), 88.6% in 2013 to 48.6%

Heart Failure 40

Heart Failure Hospital Pulmonary Laboratory 40